ISMICS 16
ISMICS 15
Home Final Program Past & Future Meetings  

Back to 2016 Annual Meeting Posters


The Mid-term Clinical Outcomes of Hybrid Procedure for Treating Patients with Multivessel Coronary Artery Diseases
Zhiyong Liu, Wei He, Qitong Lu, Jianmin Zhou, Jie Jiang.
Zhongda Hospital and School of Medicine, Southeast University, Nanjing, China.

OBJECTIVE: To evaluate the mid-term clinical outcomes of using lower partial sternotomy off-pump coronary artery bypass (OPCAB) and percutaneous coronary intervention (PCI) to treat patients with multivessel coronary diseases.
METHODS: From March of 2010 to May of 2015, 132 patients with multivessel diseases underwent hybrid procedure of OPCAB and PCI for myocardium revascularization. The male patients were 79 and the female were 53, the average age was 64.5 years. Two vessel diseases were 26 cases and triple vessel diseases were 106. Left ventricle diameters was 4.7±0.8mm, and Left ventricle EF was 0.42~0.65. All patients accepted PCI and were implanted drug-eluting stents before OPCAB. Lower partial sternotomy was used to graf LIMA to LAD under general anesthesia 3 to 5 days after PCI procedure.
RESULTS: 286 drug-eluting stents were implanted in 132 patients and all patients successfully underwent OPCAB for LIMA to LAD grafting. The average number of revascularization vessesl was 3.16. The ICU stay was 21.6 hours and the average hospital stay was 8.5 days after OPCAB. There was no perioperative myocardial infarction and no hospital mortality. All patients were followed-up for 3 to 62months and there were no major adverse cardiovascular events.
CONCLUSIONS: Our limited experiences of hybrid coronary revascularization (HCR) indicates that lower partial sternotomy OPCAB combined with PCI is a safe and feasible HCR for treating patients with multivessel coronary disease. The long-term outcomes need to be observed.


Back to 2016 Annual Meeting Posters
Copyright© 2019. International Society for Minimally Invasive Cardiothoracic Surgery.
Contact Us | Privacy Policy | All Rights Reserved.